News

Tag: COVID -19

Microbiologics Expands Virology Services to Support Drug and Vaccine Researchers and Developers
April 14, 2021 — Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens... MORE

JPEO-CBRND Investment Initiates Phase II Clinical Trial Using Tafenoquine to Treat COVID-19
March 12, 2021 — FOR IMMEDIATE RELEASE - The JPM CBRN Medical executed an agreement with 60P to study the effectiveness of an existing drug that shows promise against COVID-19.FORT DETRICK, Md. – February 22, 2021 – The Department of Defense (DOD) awarded a $5 million agreement to 60 Degrees Pharmaceuticals, LLC. (60P), to initiate a Phase II clinical trial to... MORE

American flags against a blue sky background

AstraZeneca to supply US with up to 500,000 additional doses of COVID-19 Long-Acting AntiBody combination AZD7442
March 12, 2021 — Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment... MORE

Biden Administration secures supply of new COVID-19 therapeutic treatment
February 26, 2021 — FOR IMMEDIATE RELEASE - The Biden Administration announced today that it has secured a supply of a recently authorized COVID-19 therapeutic treatment. The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) collaborated to purchase 100,000 treatment courses of a second therapeutic treatment from Eli Lilly and... MORE

A servicemember sits in a yellow shirt in front of a table of red and blue testing vials. Covi

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function
February 26, 2021 — Link to full article - https://www.prnewswire.com/news-releases/sarpac-clinical-trial-of-leukine-sargramostim-rhu-gm-csf-in-hospitalized-covid-19-patients-meets-primary-endpoint-of-significant-improvement-in-lung-function-301236275.html MORE

Two uniformed service members are in a tent. One wears PPE and a faceshield, while they use a nasal swab to collect a COVID-19 sample from the other Service member in uniform.

Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna
February 12, 2021 — FOR IMMEDIATE RELEASE - The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) have purchased an additional 100 million doses of COVID-19 vaccines from both Pfizer Inc. and Moderna Inc. to help meet demand for COVID-19 vaccines in the United States.The orders placed today bring the vaccine purchased by the U.S... MORE

The South Carolina National Guard Medical Command receives its first shipment of COVID-19 Moderna vaccinations at McEntire Joint National Guard Base, South Carolina, Dec. 22, 2020. The South Carolina National Guard is a Moderna Department of Defense (DoD) vaccine pilot program state and is provided a limited DoD allocation for South Carolina National Guard Soldiers and Airmen to have the opportunity to voluntarily take the vaccine. The South Carolina National Guard remains ready to support the counties, local and state agencies and first responders with requested resources for as long as needed in support of COVID-19 response efforts in the state.

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
November 30, 2020 — SIOUX FALLS, S.D.--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies without the need for human serum, today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19... MORE

DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
April 10, 2020 — ABERDEEN PROVING GROUND, EDGEWOOD AREA, MD. – A Department of Defense (DOD) team led by the U.S. Air Force Agile Combat Support Program Executive Office Directorate (PEO ACS) leveraged an existing Other Transaction Authority (OTA) agreement within the Countering Weapons of Mass Destruction (CWMD) Consortium to award a Negatively Pressured Conex... MORE

DOD-Funded Diagnostic Test for COVID-19 Granted Emergency Use Authorization
March 31, 2020 — JPEO-CBRND’s industry partner BioFire Defense, LLC is producing COVID-19 tests to aid in pandemic response... MORE

Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
March 24, 2020 — ALACHUA, Fla. & PLYMOUTH MEETING, Pa.--March 24, 2020--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ: INO) developing DNA medicines for infectious diseases and cancer, announced today that the Department of Defense (DOD) has awarded Ology Bioservices with a... MORE

News Search

News Archive - Search by Year and Month

2024 (40)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.